IP7

IP7
Name	Inositol pyrophosphate (IP7)
IUPAC name	1,5-bis(diphosphoinositol) (common)
Other names	Diphosphoinositol pentakisphosphate; PP-IP5
Formula	C6H18O21P7 (nominal)
Molar mass	~660 g·mol−1

IP7

IP7 is a member of the inositol pyrophosphate family implicated in eukaryotic signal transduction, metabolism, and cell cycle. It is synthesized from inositol polyphosphates by conserved kinases and hydrolyzed by pyrophosphatases; IP7 acts as a high-energy signaling molecule that modulates activities of proteins, ion channels, and metabolic pathways across organisms from Saccharomyces cerevisiae to Homo sapiens. Research on IP7 bridges structural biology, chemical synthesis, and physiology, and intersects with studies in oncology, neurobiology, and immunology.

Chemical identity and structure

IP7 denotes a diphosphoinositol pentakisphosphate species in which a single pyrophosphate (diphosphate) group is appended to a myo-inositol ring bearing five monophosphate groups. The myo-inositol scaffold links to stereospecific phosphate esters studied in X-ray crystallography and nuclear magnetic resonance spectroscopy investigations at institutions such as EMBL and Max Planck Society. Structural variants include positional isomers characterized by substitution patterns at the 1-, 3-, 4-, and 5-positions reported in studies from laboratories at Harvard University, Massachusetts Institute of Technology, and University of Cambridge. The pyrophosphate moiety confers labile phosphoanhydride bonds analogous to those in ATP and phosphocreatine, accounting for IP7's high-energy nature and biochemical reactivity examined in research from NIH groups.

Biosynthesis and metabolism

Biosynthesis of IP7 proceeds from inositol hexakisphosphate (IP6) via phosphorylation by kinases such as the inositol hexakisphosphate kinases (IP6K1, IP6K2, IP6K3) and, in some species, by diphosphoinositol pentakisphosphate kinases (PPIP5K1, PPIP5K2). Yeast pathways centered on Vip1 orthologs and metazoan pathways involving IP6Ks have been elucidated through genetic studies at laboratories including Stanford University and University of Oxford. Catabolism is mediated by diphosphoinositol polyphosphate phosphohydrolases (DIPPs) characterized by biochemical assays in research from Max Planck Institute of Biochemistry and Cold Spring Harbor Laboratory. Regulation of kinase and phosphohydrolase activities is influenced by cellular ATP levels, ionic milieu investigated by groups at University of California, San Francisco and by post-translational modifications reported from Rockefeller University.

Biological functions and signaling

IP7 participates in signaling networks by donating its high-energy pyrophosphate to phosphorylated serine residues in proteins (protein pyrophosphorylation) and by noncovalent interactions that alter protein conformation and activity. Functional outputs include modulation of Akt/PKB signaling cascades, regulation of AMP-activated protein kinase (AMPK) pathways, and influence on vesicular trafficking through effectors such as clathrin adaptors. Studies from Yale University, University of Chicago, and Johns Hopkins University link IP7 to control of ribosomal biogenesis, DNA repair machineries, and regulation of telomere-associated factors. IP7 also affects ion channels and transporters studied in electrophysiology labs at Columbia University and University College London.

Analytical methods and detection

Detection and quantification of IP7 employ radiolabeling with 32P, high-performance liquid chromatography at centers like Scripps Research, capillary electrophoresis developed at ETH Zurich, and mass spectrometry workflows advanced at Max Planck Institute for Chemical Ecology. Novel chemoenzymatic assays use recombinant IP6K enzymes and pyrophosphatases from University of California, Berkeley to resolve isomers. Chromatographic separation often uses strong anion exchange matrices optimized by teams at University of Toronto and derivatization strategies reported from Imperial College London enhance sensitivity in tandem mass spectrometry experiments. Structural studies rely on crystallography of complexes with proteins from MRC Laboratory of Molecular Biology.

Synthetic chemistry and analogs

Chemical synthesis of IP7 and stable analogs has been undertaken by organic chemistry groups at University of Cambridge, ETH Zurich, and University of Oxford to facilitate mechanistic studies. Strategies employ protecting-group schemes, phosphoramidite chemistry, and installation of methylene-bisphosphonate surrogates to generate nonhydrolyzable analogs used in binding assays by investigators at Princeton University and University of Pennsylvania. Synthetic analogs serve as probes in structural biology at Cold Spring Harbor Laboratory and in-cellulo imaging developed at University of California, San Diego.

Physiological and pathophysiological roles =

IP7 influences metabolic homeostasis, insulin signaling, and energy balance with phenotypes observed in IP6K1 knockout mice analyzed at University of Dundee and Weill Cornell Medicine. Alterations in IP7 levels correlate with tumorigenesis in models studied at MD Anderson Cancer Center and with inflammatory responses investigated at Karolinska Institutet. Neurophysiological roles are probed in studies of synaptic plasticity at MIT and University of California, Los Angeles. Dysregulation of IP7 metabolism is implicated in metabolic disorders, cancer progression, and aging phenotypes explored in long-term studies at Salk Institute and Buck Institute.

Research applications and therapeutic potential

IP7 and its metabolic enzymes are targets for drug discovery programs at biotech firms and academic translational centers including Novartis Institutes for BioMedical Research and Wellcome Trust-funded consortia. Small-molecule inhibitors of IP6K1 show efficacy in preclinical models of obesity and cancer from studies at University of Cambridge and Cold Spring Harbor Laboratory. Chemical probes and nonhydrolyzable analogs are used in high-throughput screening at Broad Institute and to dissect signaling in organoids developed at Howard Hughes Medical Institute. Ongoing clinical translation efforts focus on modulating IP7 pathways in metabolic disease, inflammatory disorders, and oncology, with collaborative consortia involving European Molecular Biology Laboratory and NIH institutes.

Category:Inositol phosphates